1 results match your criteria: "PLA General Hospital and The Key Lab of Normal Aging and Geriatric[Affiliation]"
Combating rituximab resistance by inducing ceramide/lysosome-involved cell death through initiation of CD20-TNFR1 co-localization.
Oncoimmunology
May 2016
Department of Oncology, PLA General Hospital Cancer Center, PLA School of Medicine and Key Laboratory of Cell Engineering & Antibody, Beijing and Institute for Translational Medicine, Second Military Medical University, Shanghai, People's Republic of China; National Clinical Research Center for Normal Aging and Geriatric & Institute of Geriatric, PLA General Hospital and The Key Lab of Normal Aging and Geriatric, Beijing, People's Republic of China.
Despite the success of CD20 antibody rituximab in immunotherapy, acquired resistance is one of the prime obstacles for the successful treatment of B-cell malignancies. There is an urgent need to intensify efforts against resistance in cancer treatment. Growing evidence indicated that lysosomes may form an "Achilles heel" for cancer cells by sensitizing them to death pathways.
View Article and Find Full Text PDF